RVP vs. OBIO, NSPR, FONR, SPAI, BDMD, APYX, VANI, NTRB, TELA, and LUNG
Should you be buying Retractable Technologies stock or one of its competitors? The main competitors of Retractable Technologies include Orchestra BioMed (OBIO), InspireMD (NSPR), Fonar (FONR), Safe Pro Group (SPAI), Baird Medical Investment (BDMD), Apyx Medical (APYX), Vivani Medical (VANI), Nutriband (NTRB), TELA Bio (TELA), and Pulmonx (LUNG). These companies are all part of the "medical equipment" industry.
Retractable Technologies vs. Its Competitors
Orchestra BioMed (NASDAQ:OBIO) and Retractable Technologies (NYSE:RVP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.
In the previous week, Orchestra BioMed had 10 more articles in the media than Retractable Technologies. MarketBeat recorded 10 mentions for Orchestra BioMed and 0 mentions for Retractable Technologies. Orchestra BioMed's average media sentiment score of 1.22 beat Retractable Technologies' score of 0.00 indicating that Orchestra BioMed is being referred to more favorably in the media.
Retractable Technologies has higher revenue and earnings than Orchestra BioMed. Retractable Technologies is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.
Orchestra BioMed currently has a consensus price target of $14.00, indicating a potential upside of 412.82%. Given Orchestra BioMed's stronger consensus rating and higher possible upside, research analysts clearly believe Orchestra BioMed is more favorable than Retractable Technologies.
Retractable Technologies has a net margin of -41.11% compared to Orchestra BioMed's net margin of -2,367.49%. Retractable Technologies' return on equity of -17.15% beat Orchestra BioMed's return on equity.
53.2% of Orchestra BioMed shares are owned by institutional investors. Comparatively, 7.6% of Retractable Technologies shares are owned by institutional investors. 8.1% of Orchestra BioMed shares are owned by insiders. Comparatively, 57.1% of Retractable Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Orchestra BioMed has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, Retractable Technologies has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500.
Summary
Orchestra BioMed beats Retractable Technologies on 9 of the 17 factors compared between the two stocks.
Get Retractable Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for RVP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RVP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Retractable Technologies Competitors List
Related Companies and Tools
This page (NYSE:RVP) was last updated on 9/1/2025 by MarketBeat.com Staff
